Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-DOTA-(2P-PEG4) is a radiopharmaceutical diagnostic tracer designed for positron emission tomography (PET) imaging of prostate cancer. It targets the prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer cells. The molecule is a multivalent (dimeric) PSMA ligand conjugated with a polyethylene glycol (PEG4) chain to optimize pharmacokinetics. The PEGylation and dimerization are intended to enhance tumor-targeting affinity through the multivalent effect while promoting faster renal clearance and reducing blood half-life compared to monomeric tracers. It utilizes the DOTA chelator to complex the positron-emitting radioisotope Gallium-68.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-DOTA-(2P-PEG4).